Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 5K08CA266937 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
Smartphone Technology to Alleviate Malignant Pain (STAMP) + Cognitive Behavioral Therapy for Pain (STAMP+CBT) The purpose of the study is to develop and refine the mHealth pain-CBT app intervention and carry out a randomized pilot to test the novel mHealth (Mobile health technology) intervention, which harmonizes psychological and pharmacological support for advanced cancer pain.
The name of the study smartphone application involved in this study is:
-STAMP+CBT
The purpose of the study is to make sure the app is usable and helpful for participants with cancer and to get feedback about participants experiences after using the app for four weeks. Outcomes related to pain, quality of life, and healthcare utilization will also be assessed. The cancer pain education packet and pain and medication monitoring survey are standard care. The app is intended to improve self-management of cancer-related pain.
The study will begin with Cohort A, followed by Cohort B. These two cohorts are to refine the STAMP+CBT intervention. Then a randomized pilot will be performed, and participants will be randomized into one of two study groups for the pilot: Cohort C: STAMP+CBT versus Cohort D: Digital Cancer Pain Education Packet + Usual Care. Randomization means a participant is placed into a study group by chance.
It is expected that about 60 people will take part in this research study.
The National Institutes of Health, National Cancer Institute (NIH-NCI), is funding this research study.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cohort C: STAMP + CBT App | Experimental | Permutated-block randomization and a block size of 6 will be used to randomize 60 participants to this cohort, and participants will complete:
|
|
| Cohort D: Digital Cancer Pain Education Packet + Usual Care | Other | Permutated-block randomization and a block size of 6 will be used to randomize 60 participants to this cohort, and participants will complete:
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| STAMP + CBT | Behavioral | A mobile health, smartphone application that provides tailored multi-media, cancer pain psycho-education and pain management coping skills using algorithm-based technology to provide in the moment symptom monitoring and feedback. |
| Measure | Description | Time Frame |
|---|---|---|
| Overall intervention adherence rate (Cohort C) | >70% of subjects complete any activity on the STAMP+CBT application at least 50% of days on study (4-week study period). The app will be considered feasible if this benchmark is achieved. | Up to 4 weeks |
| Overall intervention adherence rate (Cohort D) | Defined as completion of the 14- and 28-days surveys, which assesses completion of the pain and medication monitoring reports by participants in the control group. | Up to 4 weeks |
| Proportion of participants who rate app acceptability at least 4/5 on the Acceptability E-Scale (Cohort C) | Acceptability of the intervention is defined as > 80% of the participants rate the application as satisfactory and useful with a mean 4 or higher score out of 5 on the Acceptability E-Scale (Tariman 2011). The Acceptability E-Scale a 7-item measure with answer ranging from 1 "Very Difficulty/Difficult to understand/Not at all/Very unacceptable/Very dissatisfied/Not useful/Very unlikely" to 5 "Very Easy/Easy to understand/Very much/ Very acceptable/Very satisfied/Very useful/Very likely" and with a total scores range of 7 to 35 with a higher score representing greater participant acceptability. Subjects will be assigned surveys at baseline, 4 weeks, and 6 weeks. Participants will rate the app on the following 5 domains: understandability, enjoyability, ease of use, time required to use the app, and overall satisfaction. Ratings lower than 4/5 will lead to refinements. | Up to 6 weeks |
| Proportion of participants who rate educational packet acceptability at least 4/5 on the Acceptability E-Scale (Cohort D) | Acceptability of the intervention is defined as > 80% of the participants rate the application as satisfactory and useful with a mean 4 or higher score out of 5 on the Acceptability E-Scale (Tariman 2011). The Acceptability E-Scale a 7-item measure with answer ranging from 1 "Very Difficulty/Difficult to understand/Not at all/Very unacceptable/Very dissatisfied/Not useful/Very unlikely" to 5 "Very Easy/Easy to understand/Very much/ Very acceptable/Very satisfied/Very useful/Very likely" and with a total scores range of 7 to 35 with a higher score representing greater participant acceptability. Subjects will be assigned surveys at baseline, 4 weeks, and 6 weeks. Participants will rate the app on the following 5 domains: understandability, enjoyability, ease of use, time required to use the app, and overall satisfaction. Ratings lower than 4/5 will lead to refinements. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Enrolled Participants who Consented and Completed the Study (Cohort C) | Defined as the proportion of participants of the intervention group on study for the complete study period. Subjects are defined as individuals who consented and enrolled to the trial and complete study measures and either 28 days of app use (intervention group) or 28 days of education packet review (control group). Rates of completion will be compared between the intervention and control groups. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Desiree Azizoddine, PsyD | Dana-Farber Cancer Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States |
The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Data can be shared no earlier than 1 year following the date of publication
Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Digital Cancer Pain Education Packet | Behavioral | Packet including Articles from the Association for Clinical Oncology and the National Cancer Institute and the pain and medication monitoring form. |
|
| Up to 6 weeks |
| 18 months |
| Number of Enrolled Participants who Consented and Completed the Study (Cohort D) | Defined as the proportion of participants of the control group on study for the complete study period. Subjects are defined as individuals who consented and enrolled to the trial and complete study measures and either 28 days of app use (intervention group) or 28 days of education packet review (control group). Rates of completion will be compared between the intervention and control groups. | 18 months |
| Study Retention (Cohort C) | Defined as the proportion of participants of the intervention group on study for the complete study period. Subjects are defined as individuals who consented and enrolled to the trial and complete study measures and either 28 days of app use (intervention group) or 28 days of education packet review (control group). Rates of completion will be compared between the intervention and control groups. | 18 months |
| Study Retention (Cohort D) | Defined as the proportion of participants of the control group on study for the complete study period. Subjects are defined as individuals who consented and enrolled to the trial and complete study measures and either 28 days of app use (intervention group) or 28 days of education packet review (control group). Rates of completion will be compared between the intervention and control groups. | 18 months |
| Median assessment score on the system usability scale at 4 weeks (Cohort C) | Intervention usability will be assessed by the System Usability Scale (SUS), a 12-item measure rated on a 5-point Likert scale from 1 "Strongly Disagree" to 5 "Strongly Agree" with a total scores range of 0 to 100. A higher score represents greater usability. Subjects will be assigned surveys at baseline, 4 weeks, and 6 weeks. The survey at 4 weeks will assess intervention acceptability with the System Usability Scale (Brooke, 2002). The app will be considered usable if the median score on the System Usability Scale across respondents is >75. | Up to 6 weeks |
| Median assessment score on the system usability scale at 4 weeks (Cohort D) | Intervention usability will be assessed by the System Usability Scale (SUS), a 12-item measure rated on a 5-point Likert scale from 1 "Strongly Disagree" to 5 "Strongly Agree" with a total scores range of 0 to 100. A higher score represents greater usability. Subjects will be assigned surveys at baseline, 4 weeks, and 6 weeks. The survey at 4 weeks will assess control education packet acceptability with the System Usability Scale (Brooke, 2002). This information will be used to compare usability scores across intervention and control groups. | Up to 6 weeks |
| Change in Brief Pain Inventory (BPI) Pain Interference Score from Baseline to 4 and 6 Weeks (Cohort C) | Assessed by the BPI, a 7-item subscale on pain interference with answers scored on a scale from 0 "Does not interfere" to 10 "Greatly interferes." A total scores range is 0 to 70 with a higher score indicating greater pain interference. | Up to 6 weeks |
| Change in BPI Pain Interference Score from Baseline to 4 and 6 Weeks (Cohort D) | Assessed by the BPI, a 7-item subscale on pain interference with answers scored on a scale from 0 "Does not interfere" to 10 "Greatly interferes." A total scores range is 0 to 70 with a higher score indicating greater pain interference. | Up to 6 weeks |
| Change in BPI Pain Intensity Score from Baseline to 4 and 6 Weeks (Cohort C) | Assessed by the Brief Pain Inventory (BPI) pain intensity subscale, a 4-item measure on pain intensity with answers scored on a scale from 0 "No pain" to 10 "Pain as bad as you can imagine." A total scores range is 0 to 40 with a higher score indicating greater pain intensity. | Up to 6 weeks |
| Change in BPI Pain Intensity Score from Baseline to 4 and 6 Weeks (Cohort D) | Assessed by the Brief Pain Inventory (BPI) pain intensity subscale, a 4-item measure on pain intensity with answers scored on a scale from 0 "No pain" to 10 "Pain as bad as you can imagine." A total scores range is 0 to 40 with a higher score indicating greater pain intensity. | Up to 6 weeks |
| ID | Term |
|---|---|
| D010146 | Pain |
| D013001 | Somatoform Disorders |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001523 | Mental Disorders |
Not provided
Not provided